Trading Signals: DVAX Stock Price Prediction and Forecast (Thu. Feb. 19, 2004 - Fri. Dec. 22, 2023)(Dynavax Technologies Corporation)
| DVAX latest price $81.5000 (1.88%) ($80.0000 - $84.1900) on Wed. Mar. 10, 2004. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.67% (three month average) | | RSI | 32 | | Latest Price | $81.5000(1.88%) | | Stocks Behave Similarly | Similar Stock List | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support DVAX advance at 0% a week (0% probability)
TIP(3%) SHY(2%) TLT(2%) XLP(-0%) QQQ(-1%) | | Factors Impacting DVAX price | DVAX will decline at least -1.835% in a week (0% probabilities).
OIH(-6%) EWP(-6%) EEM(-6%) XLY(-5%) EWY(-5%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.835% (StdDev 3.67%) | | Hourly BBV | 0 () | | Intraday Trend | 0.5% | | | | | |
|
| 5 Day Moving Average | $82.88(-1.67%) | | 10 Day Moving Average | $83.11(-1.94%) | | 20 Day Moving Average | $0(0%) | | To recent high | -13.3% | | To recent low | 1.9% | | Market Cap | $8.925b | | | | | | |
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.July 7, 2020 DVAX is developing a vaccine candidate SCB-2019 with GlaxoSmithKline plc GSK which is in its phase 1 clinical trials. The vaccine is made up of S-Trimer protein that resembles the coronavirus spike protein and hence triggers the immune system to produce antibodies. |